Fredrick B. Hagemeister, Jr, MD, of the University of Texas MD Anderson Cancer Center, discusses whether rituximab maintenance should be used in indolent lymphomas other than follicular.
Steven P. Treon, MD, PhD, of the Dana-Farber Cancer Institute, discusses the question of what is the best upfront therapy for lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia.
Jonathan W. Friedberg, MD, of the University of Rochester Medical Center, discusses the use of rituximab as a single agent and in combination with chemotherapy, the emerging role of novel agents, and some possible explanations for the small subset of patients with inferior outcomes.
David G. Maloney, MD, PhD, of Fred Hutchinson Cancer Research Center, discusses the efficacy of chimeric antigen receptor (CAR) T cells for lymphoma and their toxicity.
Richard I. Fisher, MD, of Fox Chase Cancer Center-Temple Health, discusses this rare disease––with features between classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma––and reviews the clinical data on treatment.
Susan M. O’Brien, MD, of the University of California, Irvine, discusses the challenges of treating older patients with acute lymphoblastic leukemia and lymphoma, and the positive results with newer regimens using blinatumomab and inotuzumab.
